Planned Radiation in Axillary Management of Breast Cancer

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

Jorge Nieva, MD

July 14th 2025

Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Best Practices for the Medical Oncology Boards

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Tim Cortese

Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Potential Biomarker May Predict Outcomes/Response in RCC

Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Related Content

Kyle Doherty

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

Jorge Nieva, MD

July 14th 2025

Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Best Practices for the Medical Oncology Boards

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Tim Cortese

Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.